In a remarkable development, scientists have demonstrated that a single, localized injection of an engineered antibody can induce systemic cancer remission in some patients. Early clinical trial data, published in Cancer Cell, reveals that tumors not only shrank in the injected site but disappeared across the body in two out of twelve participants. This suggests a new approach to immunotherapy that could overcome limitations of current treatments.
The Science Behind Systemic Remission
The therapy centers around a redesigned antibody, 2141-V11, which activates CD40 receptors on immune cells. CD40 is critical for signaling the immune system to attack tumors, but previous CD40 therapies caused severe side effects due to widespread immune activation.
Ravetch’s team at Rockefeller University overcame this challenge by modifying the antibody to bind more effectively to CD40 and, crucially, by delivering the drug directly into tumors. This localized approach minimizes toxicity while maximizing the immune response. The modified antibody triggers an intense immune reaction within the tumor, recruiting immune cells that then spread throughout the body to eradicate distant metastases.
Trial Results: Unexpected Systemic Effects
The phase 1 trial involved patients with advanced melanoma, renal cell carcinoma, and breast cancer. Six out of twelve patients experienced significant tumor shrinkage. Two achieved complete remission, with all detectable cancer vanishing. Remarkably, this systemic response occurred even when only one tumor was injected.
“Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable,” says Dr. Juan Osorio, lead author of the study.
Tissue samples from treated tumors showed the formation of tertiary lymphoid structures (TLS)—organized clusters of immune cells that enhance anti-tumor immunity. These TLS were found in both injected and distant tumors, confirming the systemic effect. The therapy appears to “transform” the tumor environment, replacing cancerous cells with immune cells.
Why This Matters: Overcoming Immunotherapy Barriers
Immunotherapy has revolutionized cancer treatment, but only works for a fraction of patients (typically 25-30%). This is because not all tumors are susceptible, and even when they are, the immune system may not mount a strong enough response.
The localized CD40 agonist approach may solve both problems. By concentrating the immune attack at the tumor site, it overcomes resistance mechanisms. The systemic spread suggests that once the immune system is activated in one location, it can identify and eliminate cancer cells elsewhere.
Future Trials and Personalized Approaches
Larger phase 1 and phase 2 trials are now underway, involving nearly 200 patients with bladder, prostate, and brain cancers. Researchers are analyzing why some patients respond while others do not. Early data suggest that high clonality of T cells at the start of treatment may be a key factor.
The ultimate goal is to identify biomarkers that predict response and refine the therapy to convert non-responders into responders. If successful, this approach could transform cancer treatment by making immunotherapy effective for a much wider range of patients.
This breakthrough represents a significant step forward, offering a potential solution to one of the biggest challenges in modern oncology: unlocking the full power of the immune system to defeat cancer.
